Market size, growth to 2033 and clinical trials, side by side.
The US is the bigger HIV Drugs market: $12.6 Bn against $2.4 Bn in 2023, about 5.3 times as large.
Canada grows faster: 5.8% a year, against 3.8%. The gap still grows from $10.2 Bn to $14.1 Bn by 2033.
Clinical research: 506 active trials in the US, 33 in Canada.
| Measure | ||
|---|---|---|
| Market size, 2023 | $12.6 Bn | $2.4 Bn |
| Market size, 2033 projected | $18.3 Bn | $4.2 Bn |
| Growth a year (CAGR) | 3.8% | 5.8% |
| Money added, 2023–2033 | $5.7 Bn | $1.8 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $37 | $58 |
| Active clinical trials | 506 | 33 |
| New HIV infections people (WHO) | – | 1,900 2022 |
| Full report | US report | Canada report |
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
The US is the bigger HIV Drugs market: $12.6 Bn against $2.4 Bn in 2023, about 5.3 times as large.
Canada grows faster: 5.8% a year, against 3.8%. The gap still grows from $10.2 Bn to $14.1 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.